GLP-1 vs Mounjaro: clearing up the biggest misconception

The myth: Mounjaro is just another GLP-1 jab

The most common misconception is that all weight-loss injections are essentially the same product with different branding. They are not. GLP-1 receptor agonists like semaglutide (Wegovy) slow gastric emptying and reduce appetite by mimicking the GLP-1 gut hormone. Mounjaro does all of that, but also activates the GIP receptor, a second pathway involved in both energy metabolism and appetite regulation. The clinical result of this dual action, as reported in the SURMOUNT-1 trial and assessed by NICE in their tirzepatide appraisal (TA1026), is a larger average weight reduction than semaglutide achieves at its standard maintenance dose. This is not a marketing narrative; it is the basis on which regulators and NICE evaluated the medicine. The practical upshot for anyone researching their options is that "GLP-1" has become a loose collective term for a category, and Mounjaro sits in that category while operating differently within it. If you want to see how that difference plays out against an older GLP-1 medicine, the exenatide vs tirzepatide comparison is a useful reference point for understanding how the class has evolved. Understanding the distinction is the starting point for a sensible comparison, not a reason to assume Mounjaro is categorically superior for your situation, because individual response varies considerably and is shaped by your health history, not just the mechanism.

How the licensed medicines actually compare

The table below summarises the key factual differences between the three main UK-licensed weight-management injectables. Ozempic is included because it generates search traffic alongside these medicines, but it carries a firm note: Ozempic (also semaglutide) is licensed in the UK for type 2 diabetes, not weight loss, and should not be sought for that purpose.

The SURMOUNT-5 trial) a direct head-to-head published in the New England Journal of Medicine in 2025, running 72 weeks in adults with obesity and no diabetes, confirmed that tirzepatide produced greater average weight reduction than semaglutide 2.4mg. The Wegovy 7.2mg pen, approved by the MHRA in April 2026, narrows the gap appreciably. If you want to understand how these results translate to real eligibility thresholds, the Mounjaro overview page covers the NICE criteria in full.

Side effects, tolerability and what arriving at your door looks like

Both tirzepatide and semaglutide share a similar side-effect profile, dominated by gastrointestinal symptoms: nausea, diarrhoea, constipation, and indigestion are the most commonly reported. These tend to be most noticeable when starting treatment or after a dose step, and they settle for most people within a week or two. Tirzepatide begins at 2.5mg specifically to let the body adjust before the prescriber moves the dose up. Semaglutide starts at 0.25mg weekly for the same reason. Neither medicine should be stopped abruptly without speaking to your prescriber. Pancreatitis, though infrequent, is a recognised risk across the GLP-1 class: persistent severe stomach pain that radiates to the back needs urgent medical attention. Both medicines are Black Triangle (▼) products, meaning they carry additional MHRA monitoring. You can report any suspected side effect through the MHRA's Yellow Card scheme. When a prescription is issued through nume, the medicine arrives the next working day with DPD tracking, a standard cardboard box, nothing on the outside to indicate what's inside, and the KwikPen itself stored in a sealed carton inside. It is worth knowing what a legitimate pen looks and feels like before you open it, since counterfeit versions have been seized in large numbers by the MHRA.

Which GLP-1 medicine suits you, and how a prescriber works that out

Neither medicine is universally the better choice. The clinical picture, your BMI, your comorbidities, how you've responded to previous treatments, your contraceptive method if relevant, your preference for injection vs. tablet, shapes the decision. For a detailed look at how Mounjaro sits relative to other emerging treatments in the pipeline, the GLP-1 vs tirzepatide comparison and the tirzepatide vs Mounjaro breakdown go further on mechanism and trial data. If retatrutide (a triple agonist in late-phase trials) is on your radar, the retatrutide vs Mounjaro page covers what is and is not yet established. Cost is another real consideration: the Mounjaro price guide explains the private market honestly, including how Eli Lilly's September 2025 list-price change affected what providers charge. The right starting point, regardless of which medicine interests you, is a consultation with a prescriber who can read your full picture. Our clinical team, including our lead prescriber Mostafa Damghani, reviews every consultation personally. That is what a same-day clinical review means in practice. To get started, visit the treatment page and begin your free consultation.